MANNKIND CORP Payments to Acquire Debt Securities, Available-for-sale
MANNKIND CORP (MNKD) reported Payments to Acquire Debt Securities, Available-for-sale of $70.13 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-08.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2022-11-08
- MANNKIND CORP payments to acquire debt securities, available-for-sale for the quarter ending 2022-09-30 was $1.66M, a 98.28% decline year-over-year.
- MANNKIND CORP payments to acquire debt securities, available-for-sale for the quarter ending 2022-06-30 was $12.48M, a 88.49% decline year-over-year.
- MANNKIND CORP payments to acquire debt securities, available-for-sale for the quarter ending 2022-03-31 was $55.99M, a 83.92% increase year-over-year.
- MANNKIND CORP payments to acquire debt securities, available-for-sale for the quarter ending 2021-09-30 was $96.49M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month |
|---|---|---|---|
| 2022-09-30 | $1.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $14.14M derived: sum of 2 quarters · filed 2022-11-08 | $70.13M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $12.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $68.47M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $55.99M 10-Q · filed 2022-05-05 | ||
| 2021-09-30 | $96.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $204.96M derived: sum of 2 quarters · filed 2022-11-08 | $235.41M 10-Q · filed 2022-11-08 |
| 2021-06-30 | $108.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $138.92M 10-Q · filed 2022-08-09 | |
| 2021-03-31 | $30.44M 10-Q · filed 2022-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |